Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 289 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacogenetic Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenomics of Thiazolidinediones

NCT01135394
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
35 Years to 64 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 1, 2026, 10:29 AM EDT
Completed No phase listed Observational

Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer

NCT00283608
View directory record Official record
Conditions
Breast Cancer
Interventions
Single nucleotide polymorphism (SNP), high performance liquid chromatography, measurements by DXA, questionnaire administration
Genetic · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Oct 1, 2026, 10:29 AM EDT
Terminated Phase 2 Interventional Results available

RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy

NCT01193868
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 1, 2026, 10:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Carriers in the PAPI Study

NCT03188705
View directory record Official record
Conditions
Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Artery Occlusion, Aspirin Sensitivity, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Platelet Thrombus
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 1, 2026, 10:29 AM EDT
Terminated No phase listed Observational

Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy

NCT00471653
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Thrombocytopenia
Interventions
temozolomide, comparative genomic hybridization, polymorphism analysis, laboratory biomarker analysis, pharmacological study, radiation therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Duarte, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 1, 2026, 10:29 AM EDT
Terminated Phase 1 Interventional

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

NCT01907802
View directory record Official record
Conditions
BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
Interventions
Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 1, 2026, 10:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Trial of Precision Medicine in Emergency Departments

NCT06448091
View directory record Official record
Conditions
Pharmacogenomic Drug Interaction
Interventions
Panel-based pharmacogenetic genotyping
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
40 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 1, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal

NCT00664404
View directory record Official record
Conditions
Smoking
Interventions
Functional Magnetic Resonance Imaging (fMRI)
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 1, 2026, 10:29 AM EDT
Completed Not applicable Interventional Results available

Integrating Pharmacogenetics In Clinical Care

NCT02871934
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
SLCO1B1 Genotype
Genetic
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 75 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 1, 2026, 10:29 AM EDT
Recruiting No phase listed Observational

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

NCT06580106
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Biospecimen samples
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 1, 2026, 10:29 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Naproxen Pharmacogenetic Study (Project 1, Aim 2)

NCT04449471
View directory record Official record
Conditions
Pharmacogenetics
Interventions
Naproxen tablet
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 1, 2026, 10:29 AM EDT
Completed Not applicable Interventional Results available

Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention

NCT02508116
View directory record Official record
Conditions
Acute Coronary Syndrome, Cardiovascular Diseases
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 1, 2026, 10:29 AM EDT
Completed No phase listed Observational

Prospective Observational Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Patients Undergoing Elective Surgical Procedures

NCT02605343
View directory record Official record
Conditions
Acute Pain, Surgery
Interventions
NeuroIDgenetix Test Panel
Other
Lead sponsor
AltheaDx
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 1, 2026, 10:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia

NCT00418015
View directory record Official record
Conditions
Labor Pain, Post-cesarean Delivery
Interventions
Blood Draw
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 1, 2026, 10:29 AM EDT
Recruiting Phase 4 Interventional

Vascular Trial Associated Registry Pilot

NCT07076082
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
45 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 1, 2026, 10:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacogenomics and Post-Operative Nausea and Vomiting

NCT03503292
View directory record Official record
Conditions
Postoperative Nausea
Interventions
Granisetron, Ondansetron
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 1, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

NCT02541942
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 1, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

NCT00025363
View directory record Official record
Conditions
Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma
Interventions
vincristine sulfate, irinotecan hydrochloride, cyclophosphamide, doxorubicin hydrochloride, ifosfamide, etoposide, tirapazamine, filgrastim, sargramostim, pharmacological study, pharmacogenomic studies, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 20 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 1, 2026, 10:29 AM EDT
Completed Not applicable Interventional

Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression

NCT04469322
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major, Depression, Bipolar, Depressive Episode
Interventions
Mental Health DNA Insight Test (Pathway Genomics), Sham Test
Diagnostic Test
Lead sponsor
San Diego Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 1, 2026, 10:29 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:

NCT06322238
View directory record Official record
Conditions
Pharmacogenomic Drug Interaction, Side Effect of Drug, Ineffective Drug Action, Drug Metabolism, Poor, CYP2D6-Related, Drug Metabolism, Poor, CYP2C19-Related
Interventions
PGx panel test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 1, 2026, 10:29 AM EDT
Terminated No phase listed Observational

Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents

NCT00207948
View directory record Official record
Conditions
HIV Infections
Interventions
Dose adjustment of Kaletra
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
4 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Oct 1, 2026, 10:29 AM EDT
Recruiting Not applicable Interventional

Informing Pain Treatment Using Pharmacogenomic Analysis

NCT06511401
View directory record Official record
Conditions
Adult Patients Who Are Receiving Oncologic Care
Interventions
Pharmacogenomic (PGx) results.
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 1, 2026, 10:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers

NCT01104376
View directory record Official record
Conditions
Efavirenz, Metabolism and Pharmacokinetics Changes
Interventions
Efavirenz, voriconazole
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 1, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers

NCT02371889
View directory record Official record
Conditions
Alcoholism, Alcohol Use Disorder (AUD)
Interventions
Topiramate, Medical Management, Inactive Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 1, 2026, 10:29 AM EDT